Early chronic fasudil treatment rescues hippocampal alterations in the Ts65Dn model for down syndrome

Rosa López-Hidalgo,Raúl Ballestín,Lorena Lorenzo,Sandra Sánchez,José Miguel Blasco-Ibáñez,Carlos Crespo,Juan Nacher,Emilio Varea

DOI: https://doi.org/10.1016/j.neuint.2024.105679

IF: 4.297

2024-02-04

Neurochemistry International

Abstract:Down syndrome (DS) is the most common genetic disorder associated with intellectual disability. To study this syndrome, several mouse models have been developed. Among the most common is the Ts65Dn model, which mimics most of the alterations observed in DS. Ts65Dn mice, as humans with DS, show defects in the structure, density, and distribution of dendritic spines in the cerebral cortex and hippocampus. Fasudil is a potent inhibitor of the RhoA kinase pathway, which is involved in the formation and stabilization of dendritic spines. Our study analysed the effect of early chronic fasudil treatment on the alterations observed in the hippocampus of the Ts65Dn model. We observed that treating Ts65Dn mice with fasudil induced an increase in neural plasticity in the hippocampus: there was an increment in the expression of PSA-NCAM and BDNF, in the dendritic branching and spine density of granule neurons, as well as in cell proliferation and neurogenesis in the subgranular zone. Finally, the treatment reduced the unbalance between excitation and inhibition present in this model. Overall, early chronic treatment with fasudil increases cell plasticity and eliminates differences with euploid animals.

biochemistry & molecular biology,neurosciences